A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

NCT ID: NCT03352453

Last Updated: 2020-08-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-15

Study Completion Date

2019-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rapastinel 450mg

Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.

Group Type EXPERIMENTAL

Rapastinel

Intervention Type DRUG

Rapastinel pre-filled syringes for weekly IV injections.

Placebo

Placebo-matching rapastinel weekly IV injections.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo-matching rapastinel pre-filled syringes for weekly IV injections.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapastinel

Rapastinel pre-filled syringes for weekly IV injections.

Intervention Type DRUG

Placebo

Placebo-matching rapastinel pre-filled syringes for weekly IV injections.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for MDD
* Current major Depressive episode of at least 4 weeks and not exceeding 24 months in duration at visit 1
* Have current, ongoing suicidality (ideation or behavior) of sufficient severity to warrant hospitalization based on the judgment of the investigator
* If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.

Exclusion Criteria

* DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 1 month before Visit 1.
* Lifetime history or currently meet DSM-5 criteria for:

1. Schizophrenia spectrum or other psychotic disorder
2. Bipolar or related disorder
3. Major neurocognitive disorder
4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study.
5. Dissociative disorder
6. Posttraumatic stress disorder
7. MDD with psychotic features
* Significant homicidal ideation or at imminent risk of injuring others or causing significant damage to property, as judged by the investigator.
* Prior participation in any investigational study of rapastinel/GLYX-13
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Naurex, Inc, an affiliate of Allergan plc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jenna Hoogerheyde

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Collaborative NeuroScience Network, LLC

Garden Grove, California, United States

Site Status

Behavioral Research Specialists, LLC

Glendale, California, United States

Site Status

Asclepes Research Centers

Panorama City, California, United States

Site Status

Institute of Living

Hartford, Connecticut, United States

Site Status

Innovative Clinical Research, Inc

Hialeah, Florida, United States

Site Status

Research Centers of America, LLC

Oakland Park, Florida, United States

Site Status

Atlanta Center for Medical Research (ACMR)

Atlanta, Georgia, United States

Site Status

Alexian Brothers Center for Psychiatric Research

Hoffman Estates, Illinois, United States

Site Status

Lake Charles Clinical Trials

Lake Charles, Louisiana, United States

Site Status

CBH Health

Gaithersburg, Maryland, United States

Site Status

Altea Research Institute

Las Vegas, Nevada, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Cincinnati VA Medical Center

Cincinnati, Ohio, United States

Site Status

Pillar Clinical Research, LLC

Richardson, Texas, United States

Site Status

Carilion Medical Center, a Virginia Nonprofit Corporation

Roanoke, Virginia, United States

Site Status

Department of Veterans Affairs Salem VA Medical Center

Salem, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.allerganclinicaltrials.com

Additional information on study locations near you may be found at AllerganClinicalTrials.com, please contact [email protected] for assistance.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAP-MD-20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.